Please wait while the formulary information is being retrieved.
RUBRACA (RUCAPARIB CAMSYLATE)
- Malignant neoplasm of fallopian tube
- Malignant neoplasm of ovary with BRCA mutation
- Malignant neoplasm of the ovary
- Primary malignant neoplasm of peritoneum
200 mg tablet
- 2 tablets (400 mg) by oral route every 12 hours
250 mg tablet
- 2 tablets (500 mg) by oral route every 12 hours
300 mg tablet
- 2 tablets (600 mg) by oral route every 12 hours
Malignant neoplasm of fallopian tube
- 1 tablet (300 mg) by oral route every 12 hours
- 2 tablets (400 mg) by oral route every 12 hours
- 2 tablets (500 mg) by oral route every 12 hours
- 3 tablets (600 mg) by oral route every 12 hours
- 2 tablets (600 mg) by oral route every 12 hours
Malignant neoplasm of ovary with BRCA mutation
- 1 tablet (300 mg) by oral route every 12 hours
- 2 tablets (400 mg) by oral route every 12 hours
- 2 tablets (500 mg) by oral route every 12 hours
- 3 tablets (600 mg) by oral route every 12 hours
- 2 tablets (600 mg) by oral route every 12 hours
Malignant neoplasm of the ovary
- 1 tablet (300 mg) by oral route every 12 hours
- 2 tablets (400 mg) by oral route every 12 hours
- 2 tablets (500 mg) by oral route every 12 hours
- 3 tablets (600 mg) by oral route every 12 hours
- 2 tablets (600 mg) by oral route every 12 hours
Primary malignant neoplasm of peritoneum
- 1 tablet (300 mg) by oral route every 12 hours
- 2 tablets (400 mg) by oral route every 12 hours
- 2 tablets (500 mg) by oral route every 12 hours
- 3 tablets (600 mg) by oral route every 12 hours
- 2 tablets (600 mg) by oral route every 12 hours
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
- Myelodysplastic syndrome
Contraindicated
- Pregnancy
Severe
Moderate
- None
RUBRACA (RUCAPARIB CAMSYLATE)
- Malignant neoplasm of fallopian tube
- Malignant neoplasm of ovary with BRCA mutation
- Malignant neoplasm of the ovary
- Primary malignant neoplasm of peritoneum
- Abnormal hepatic function tests
- Anemia
- Neutropenic disorder
- Thrombocytopenic disorder
- Acute abdominal pain
- Anorexia
- Constipation
- Diarrhea
- Dysgeusia
- Dyspnea
- Fatigue
- General weakness
- Hypercholesterolemia
- Nausea
- Pharyngitis
- Stomatitis
- Vomiting
More Frequent
Severe
Less Severe
- Palmar-plantar erythrodysesthesia
- Dizziness
- Fever
- Pruritus of skin
- Skin photosensitivity
- Skin rash
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myeloid leukemia
- Myelodysplastic syndrome
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Rucaparib
No safety and efficacy established.
- 1 Day – 18 Years
- No safety and efficacy established.
Rucaparib
- Severity Level:
D
- Additional Notes: Based on drug pharmacology dev tox may be possible
Contraindicated
Rucaparib
Mfg rec holding breastfeeding during & 2 weeks after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfg rec holding breastfeeding during & 2 weeks after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Malignant neoplasm of fallopian tube | |
| C57.0 | Malignant neoplasm of fallopian tube |
| C57.00 | Malignant neoplasm of unspecified fallopian tube |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
| Malignant neoplasm of ovary with BRCA mutation | |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
| Malignant neoplasm of the ovary | |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
| Primary malignant neoplasm of peritoneum | |
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| 0-9 | A-Z |
|---|---|
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C56 | Malignant neoplasm of ovary |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C57.0 | Malignant neoplasm of fallopian tube |
| C57.00 | Malignant neoplasm of unspecified fallopian tube |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
Formulary Reference Tool